Oxford Science Enterprises Secures £15m Investment from Aviva
Deal News | Mar 12, 2025 | UK Tech Funding
Oxford Science Enterprises, backed by a strategic partnership with the University of Oxford, has received a £15 million injection from Aviva, a major insurance provider. This investment aims to support spinout companies within the Oxford-Cambridge corridor, a region seen as crucial for UK's growth. Aviva Investors’ managing director, Ben Luckett, emphasized the importance of strategic partnerships in delivering strong outcomes for investors and savers. Alongside the spinout fund, Aviva will also place £6.6 million into Alloyed, a company specializing in advanced alloys. Oxford Science Enterprises, established in 2015, has raised over £850 million and invested more than £2.5 billion in over 100 spinouts, highlighting its significant role in fostering innovation within high-growth science and technology sectors.
Sectors
- Venture Capital
- Insurance
- Technology
Geography
- United Kingdom – The investment is aimed at bolstering innovation within the Oxford-Cambridge corridor, a significant region for UK economic growth.
Industry
- Venture Capital – The article highlights Aviva’s investment in Oxford Science Enterprises for supporting spinout companies, a common activity in the venture capital industry.
- Insurance – Aviva, a major insurance company, is making strategic investments, demonstrating its role in the financial and insurance sectors.
- Technology – Oxford Science Enterprises focuses on science and technology spinouts, aligning with the technology industry.
Financials
- £15m – The amount invested by Aviva in Oxford Science Enterprises to support spinouts.
- £6.6m – The amount invested by Aviva in Alloyed, a portfolio company of Oxford Science Enterprises.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Aviva | Investor | Company | A major insurance and financial services company providing a significant investment in Oxford Science Enterprises. |
| Oxford Science Enterprises | Target | Company | A firm investing in spinout companies, backed by the University of Oxford, benefiting from Aviva's investment. |
| University of Oxford | Partner | Company | Partnering with Oxford Science Enterprises to support spinout companies through investments. |
| Ben Luckett | Managing Director of Venture and Strategic Capital | Person | Manages Aviva Investors, commenting on the strategic importance of the investment. |
| Alloyed | Portfolio Company | Company | A portfolio company of Oxford Science Enterprises, receiving additional investment for its advanced alloys. |